LB Pharmaceuticals, Inc. (LBRX)
42.47
+0.33
(+0.78%)
USD |
NASDAQ |
Sep 18, 16:00
42.37
-0.10
(-0.24%)
After-Hours: 20:00
LB Pharmaceuticals Cash from Operations (Quarterly) : -37.63M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -37.63M |
| March 31, 2026 | -23.29M |
| December 31, 2025 | -18.10M |
| September 30, 2025 | -3.373M |
| June 30, 2025 | -5.604M |
| March 31, 2025 | -8.128M |
| Date | Value |
|---|---|
| December 31, 2024 | -5.665M |
| September 30, 2024 | -22.04M |
| June 30, 2024 | -15.78M |
| March 31, 2024 | -9.573M |
| March 31, 2023 | -0.757M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Ligand Pharmaceuticals, Inc. | 24.02M |
| Neumora Therapeutics, Inc. | -39.97M |
| ANI Pharmaceuticals, Inc. | 56.67M |
| Corcept Therapeutics, Inc. | 33.54M |
| Veru, Inc. | -5.467M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 0.089M |
| Cash from Financing (Quarterly) | -0.019M |
| Free Cash Flow | -82.83M |
| Free Cash Flow Per Share (Quarterly) | -1.261 |
| Free Cash Flow to Equity (Quarterly) | -39.74M |
| Free Cash Flow to Firm (Quarterly) | -37.99M |
| Free Cash Flow Yield | -7.16% |